Finasteride · 5 min read

Finasteride and minoxidil: how they differ

Two medicines for the same hair loss, with almost nothing in common: not the mechanism, not the form, not the dispensing rules, not the side effects. What the official documents say.

Calvap editorial team · Updated · 8 sources

You searched “balding treatment” and two names keep coming up: finasteride and minoxidil. On forums they are mentioned in the same breath, as if they were two versions of the same product. Yet they have almost nothing in common: not the mechanism, not the form, not the pharmacy rules, not the side effects.

Here is what the official leaflets, the French medicines agency (ANSM) and dermatologists say, point by point. Choosing a treatment is something you do with a doctor.

How each one works

Androgenetic alopecia, or “hereditary” hair loss, is driven by a hormone made from testosterone: dihydrotestosterone, or DHT. Under its influence, some scalp follicles shrink and produce thinner and thinner hairs.

Finasteride acts upstream. It blocks an enzyme, type II 5-alpha reductase, which converts testosterone into DHT2. Less DHT in the scalp means fewer follicles shrinking3. Its first expected effect is that hair loss stabilises1.

Topical minoxidil does not touch hormones. It stimulates growth and slows shedding, but exactly how it works is not fully understood1. The leaflet says the same: the precise mechanism is unknown6. At the start, it can make more hair fall for a few weeks, as described in the shedding in the first weeks of minoxidil.

Who it is for, and in what form

Finasteride for hair loss comes as a tablet and, more recently, as a spray applied to the scalp. Both are licensed for men aged 18 to 41 with early-stage androgenetic alopecia23. The tablet leaflet states that its efficacy has not been established for advanced hair loss or for a receding hairline at the temples2, which matters if your hair loss is mostly at the temples. It is contraindicated in women and must not be used in children2.

Minoxidil comes as a lotion or a foam and is used by both men and women1. In France, the 2% solution is licensed for adults, men or women5; the 5% solution is for men aged 18 to 65 only6.

Prescription and the signed form

Minoxidil lotion is sold without a prescription56. Finasteride is prescription-only, and in France the rules changed in 2026.

Since 16 April 2026 for a new treatment, and since 16 June 2026 for every repeat, French pharmacists only dispense finasteride tablets on presentation of a shared information form, signed by both the doctor and the patient4. It is valid for one year and must be renewed every year. It replaces the information document introduced in 20194.

The form covers the psychiatric and sexual risks, the possibility that some effects persist after stopping, the importance of taking time to think before starting, and the need for regular medical follow-up4. A patient card is also being added to every pack4. To prepare for that appointment, you can use our list of questions to ask your doctor.

Side effects

For finasteride, two groups of effects are the subject of ANSM warnings.

Psychiatric effects: low mood, depression, anxiety, suicidal thoughts24. In 2025, at the ANSM’s request, the European Medicines Agency re-evaluated the medicine and confirmed the risk of suicidal thoughts4. The official instruction is clear: if psychiatric symptoms appear, stop the treatment and see a doctor urgently4.

Sexual effects: lower sex drive, erection problems, reduced ejaculate volume2. In the trials, they affected slightly more men on finasteride than on placebo in the first year.

How many men had sexual side effects in the first year of the trials?
On finasteride3.8%
On placebo2.1%

Few men in either group, slightly more on finasteride.

Clinical trials, first 12 months, finasteride tablet leaflet.2

In these trials, about 1% of men in each group stopped because of these effects2. According to the French Society of Dermatology, they are reversible in two cases out of three1. The leaflet also lists sexual effects that persist after stopping, with unknown frequency2. The European S3 guideline describes these persistent complaints as “post-finasteride syndrome” and notes that a link to the drug remains hard to establish7.

The leaflet also lists, with unknown frequency: breast tenderness or enlargement, testicular pain, blood in the semen, infertility or poor semen quality, palpitations and allergic reactions2. Cases of breast cancer have been reported in treated men, and finasteride lowers PSA, a prostate marker, which a doctor needs to know to interpret a blood test2. In its trial, the spray caused fewer sexual effects than the tablet, but its leaflet lists the same possible effects as the tablet3.

For minoxidil, the known effects are mainly local: irritation, flaking, itching, redness and dryness of the scalp6. Hair can grow away from the treated area. More rarely, low blood pressure and chest pain6.

Pregnancy: different precautions

Finasteride is contraindicated in women because it can cause malformation in a male foetus13. A woman who is or could be pregnant must not handle broken or crushed tablets2 or come into contact with the spray3. As for semen, the NHS says only very small amounts of finasteride pass into it; manufacturers still recommend a condom, though most experts consider the risk low8. Men on treatment must not donate blood1.

For minoxidil, the 2% solution leaflet advises not using it during pregnancy as a precaution, and avoiding it while breastfeeding5. The French Society of Dermatology lists it as contraindicated in pregnancy1.

What they have in common

Both only work while you use them1. After stopping finasteride, the benefits start to fade around the 6th month and are gone within 9 to 12 months2. After stopping minoxidil, a return to the starting point is expected within 3 to 4 months6.

Both also take patience. The S3 guideline sets 6 months as the minimum time to judge finasteride’s effect on shedding, and 12 months for regrowth7. For the details, see when to judge finasteride’s effect and when to judge minoxidil lotion.

Tracking the effect in photos

Whatever treatment you decide on with your doctor, the next question is always the same: is it making a difference? The mirror is a poor judge. Hair loss that stabilises doesn’t show from one day to the next, and bathroom lighting changes everything.

What does answer it is comparable photos: same angle, same light, same distance, once a week. Calvap overlays your previous photo as a ghost so you can line up exactly the same position, and places your photos on a timeline alongside your treatment journal. You can note how you feel there too, mood included. At your follow-up appointment, you bring dated facts.

Sources

  1. Société Française de Dermatologie (dermato-info): tests and treatments for androgenetic alopecia (in French)
  2. French public medicines database: summary of product characteristics and leaflet for a finasteride tablet for hair loss (in French)
  3. French public medicines database: summary of product characteristics and leaflet for finasteride spray (in French)
  4. ANSM: “Finasteride 1 mg: a shared information form soon required for every dispensing” (2026, updated 15/06/2026) (in French)
  5. French public medicines database: leaflet and summary of product characteristics for a 2% minoxidil solution (in French)
  6. French public medicines database: leaflet and summary of product characteristics for a 5% minoxidil solution (in French)
  7. European S3 guideline on androgenetic alopecia (European Dermatology Forum, Kanti et al., update published in 2018)
  8. NHS: Fertility and pregnancy while taking finasteride

Calvap is coming to Android

Leave your email: we’ll write once, on launch day.

One email, when Android launches. Nothing else, never sold.